Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double CAR t attack: new hope for kids with tough leukemia

NCT ID NCT05674175

Recruiting now Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times

Summary

This study tests a combination of two types of engineered immune cells (CAR T cells) in children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to treatment. The goal is to see if giving both anti-CD19 and anti-CD22 CAR T cells together is safe and works better than one alone. Up to 93 participants will receive the treatment and be monitored for side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B LINEAGE LYMPHOBLASTIC LYMPHOMA B LINEAGE LYMPHOBLASTIC LYMPHOMA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA